Indeed, anti-CTLA-4 and anti-PD(L)-1 are associated with the reduced survival and inhibitory functions of CD4+ CD25+ regulatory T cells (Treg), an increased proportion of type 17 T helper cells (anti-CTLA-4) and cytokine production, in addition to the induction of cross-reactivity between anti-tumor T cells and antigens on healthy cells, leading to autoantibody production, tissue injury and auto-immune diseases [7]. Here, CTLA4 is linked to neoplasm.